Literature DB >> 2219580

The case for no initial treatment of localized prostate cancer.

P H Smith1.   

Abstract

This contribution summarizes the evidence from the natural history and pathology of this disease that, given the high incidence of latent cancer, a policy of radical treatment at diagnosis will represent over-treatment in the majority of cases. As yet, neither radical prostatectomy nor radical radiotherapy has been shown to be effective in managing the poorly differentiated tumor in the patient with "localized" disease. For the patient with well-differentiated disease, there is little evidence that early treatment is mandatory, because the majority of these patients will not die of prostatic cancer. The adoption of a policy of diagnosis followed by active surveillance would spare many patients the hazard and discomfort of a major operation or of a course of radiotherapy, would minimize expenditure, and would ensure that treatment was given only to those patients in whom progression had been demonstrated. Such an approach is almost certain to be as effective as treatment at diagnosis. Confirmation of this view is likely to be obtained from the existing studies of immediate versus delayed orchiectomy or LHRH therapy currently being undertaken by the Urological Working Party of the Medical Research Council in the United Kingdom and the Urological Group of the EORTC within Europe.

Entities:  

Mesh:

Year:  1990        PMID: 2219580

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

Review 1.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 2.  Screening for prostate cancer. Implications for drug therapy.

Authors:  R H Harwood
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

3.  Immunophenotypic Characterization of Benign and Malignant Prostatic Lesions.

Authors:  R Lakhtakia; R Bharadwaj; V K Kumar; P Mandal; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Is active surveillance an appropriate approach to manage prostate cancer patients with Gleason Score 3+3 who met the criteria for active surveillance?

Authors:  Saleh Ghiasy; Amir Reza Abedi; Afshin Moradi; Seyed Yousef Hosseini; Morteza Fallah Karkan; Ghazal Sadri; Mohammadreza Davari
Journal:  Turk J Urol       Date:  2018-11-19

5.  Screening for prostate cancer. How can patients give informed consent?

Authors:  K G Marshall
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.